Arrowhead Pharmaceuticals (ARWR) Cash & Equivalents (2010 - 2026)
Arrowhead Pharmaceuticals (ARWR) posted Cash & Equivalents of $188.5 million for Q1 2026, down 6.52% on a QoQ basis from $201.6 million in Q4 2025, and up 1.5% year-over-year from $185.7 million in Q1 2025.
Arrowhead Pharmaceuticals (ARWR) Cash & Equivalents (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $188.5 million for Q1 2026.
- Quarterly Cash & Equivalents rose 1.5% year-over-year to $188.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $188.5 million (up 1.5% YoY) and the FY2025 annual result came in at $226.5 million, up 120.62% from the prior year.
- Cash & Equivalents was $188.5 million for Q1 2026 at Arrowhead Pharmaceuticals, down from $201.6 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $226.5 million in Q3 2025 and bottomed at $53.9 million in Q4 2024.
- A 5-year average of $131.3 million and a median of $127.7 million in 2024 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 76.8% — and 2025, when it jumped 274.18%.
- Arrowhead Pharmaceuticals' Cash & Equivalents stood at $202.2 million in 2022, then slumped by 71.22% to $58.2 million in 2023, then slipped by 7.43% to $53.9 million in 2024, then soared by 274.18% to $201.6 million in 2025, then decreased by 6.52% to $188.5 million in 2026.
- Business Quant data shows ARWR's Cash & Equivalents at $188.5 million in Q1 2026, $201.6 million in Q4 2025, and $226.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 82.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.49 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 3.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 440.94 Mn |
| 10 | Arrowhead Pharmaceuticals | 11.98 Bn | 10.18 Bn | - | 188.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 188.50 Mn |
| Dec 31, 2025 | 201.64 Mn |
| Sep 30, 2025 | 226.55 Mn |
| Jun 30, 2025 | 129.80 Mn |
| Mar 31, 2025 | 185.71 Mn |
| Dec 31, 2024 | 53.89 Mn |
| Sep 30, 2024 | 102.69 Mn |
| Jun 30, 2024 | 69.40 Mn |
| Mar 31, 2024 | 127.70 Mn |
| Dec 31, 2023 | 58.22 Mn |
| Sep 30, 2023 | 110.89 Mn |
| Jun 30, 2023 | 105.33 Mn |
| Mar 31, 2023 | 134.96 Mn |
| Dec 31, 2022 | 202.25 Mn |
| Sep 30, 2022 | 108.01 Mn |
| Jun 30, 2022 | 139.44 Mn |
| Mar 31, 2022 | 86.40 Mn |
| Sep 30, 2021 | 184.43 Mn |
| Jun 30, 2021 | 326.00 Mn |
| Mar 31, 2021 | 372.38 Mn |